(NASDAQ: EDIT) Editas Medicine's forecast annual revenue growth rate of 82.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Editas Medicine's revenue in 2023 is $19,712,000.On average, 6 Wall Street analysts forecast EDIT's revenue for 2023 to be $2,126,350,896, with the lowest EDIT revenue forecast at $689,770,850, and the highest EDIT revenue forecast at $3,448,509,400. On average, 4 Wall Street analysts forecast EDIT's revenue for 2024 to be $5,246,010,440, with the lowest EDIT revenue forecast at $655,285,756, and the highest EDIT revenue forecast at $12,583,541,830.
In 2025, EDIT is forecast to generate $8,203,659,012 in revenue, with the lowest revenue forecast at $3,448,509,400 and the highest revenue forecast at $12,958,808,623.